BioLife Solutions, Inc. (BLFS) Earnings
BioLife Solutions, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $0.03. BLFS has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -235.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.01 | $0.04 | +300.0% | $28M | +7.2% |
| Aug 7, 2025 | $-0.02 | $-0.33 | -1556.7% | $25M | -1.0% |
| May 8, 2025 | $-0.03 | $0.04 | +233.3% | $24M | +7.7% |
| Mar 3, 2025 | $-0.06 | $-0.01 | +83.3% | $3M | -84.3% |
| Aug 8, 2024 | $-0.14 | $-0.06 | +57.1% | $28M | +18.3% |
| May 9, 2024 | $-0.26 | $-0.19 | +26.9% | $32M | +22.0% |
| Feb 29, 2024 | $-0.36 | $-0.30 | +16.7% | $33M | -2.0% |
| Nov 9, 2023 | $-0.38 | $-0.67 | -76.3% | $33M | -1.5% |
| Mar 16, 2023 | $-0.19 | $-1.15 | -505.3% | $44M | +2.3% |
| Nov 9, 2022 | $-0.18 | $-0.23 | -27.8% | $41M | -3.1% |
| Aug 9, 2022 | $-0.20 | $-1.71 | -755.0% | $41M | +3.5% |
| Feb 28, 2022 | $-0.16 | $-0.37 | -131.3% | $37M | +4.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Good afternoon, welcome to the call. Roderick DeGrief mentioned 2026 started solid with 25% revenue growth and 15% adjusted EBITDA growth vs prior year. BPM drove growth, over 85% of revenue. Market position strengthened with BPM in 17 approved therapies and visibility into 9 more. Cell seal vials and HPL lines growing. Focus on cross-selling and strategic initiatives. Operating leverage seen. Mentioned cell therapy landscape trends.
Guidance
Affirming 2026 guidance: revenue 112.5 to 115 million, growth 17 - 20%. Expect continued operating and adjusted EBITDA margin expansion, full year positive gap net income.
Segment performance
Total revenue reached $27.5 million, increasing 25% year-over-year. Adjusted EBITDA was $6.2 million, or 22% of revenue. BPM represents over 85% of total revenue. Gap gross margin for Q1 2026 was 64%, adjusted gross margin was 64%.
Risks & headwinds
Gross margin and adjusted EBITDA as percent of revenue declined due to bag yield dynamics. Also, biotech funding impact on early stage customers (though minimal).
Analyst Q&A
Q: On bags, clarification on margins and scrap.
A: Work with customers, 90-day notice, on track.
Q: Sector level biotech funding.
A: Funding impact minimal on BioLife, bulk revenue from well-capitalized firms.
Q: Cryo case commercial.
A: Received award, many validations, waiting for customer announcement.
Q: Homebrew share in cell therapy.
A: Numbers in favor of BioLife, hard to justify homebrew.
Q: R&D expense.
A: Related to Center of Excellence and internal projects.
Q: Commercial BPM customers revenue.
A: Target 55% realistic near term.
Q: Plurisix and QKIND deal.
A: No direct revenue impact from that deal.